AHA, hospitals file new push to block 340B rebate program: 6 things to know

Advertisement

The American Hospital Association and other plaintiffs asked a federal court Nov. 16 to block HRSA’s 340B rebate program before it takes effect Jan. 1, according to a reply brief filed in the U.S. District Court for the District of Maine.

Here are six things to know:

  1. The filing replies to oppositions from HHS and drugmaker intervenors to the plaintiffs’ motion for a preliminary injunction in American Hospital Association v. Kennedy. The plaintiffs ask the court to preliminarily enjoin the rebate program and any approvals of drug companies’ applications to participate.
  1. The plaintiffs argue HHS did not heed the court’s earlier instruction to “fortify” the program after a December 2025 ruling and that its revised program fails the Administrative Procedure Act’s reasoned decision-making standard.
  1. The brief says HRSA’s only calculation of the program’s costs is $537 million a year for covered entities to submit claims data, a figure based on an estimate that submissions will take five hours a week. The plaintiffs say neither HHS nor the intervenors explain where the estimate comes from and that record evidence shows far more labor is needed.
  2. The plaintiffs say HRSA excluded financing “float” costs and relied on an outdated version of an IQVIA study. The updated study calculated $53.7 million in annual interest costs for just 10 drugs in the program, according to the brief.
  1. On benefits, the plaintiffs say HHS “says almost nothing” about what the program would deliver and does not quantify those benefits, so the court cannot judge whether they bear a rational relationship to costs. They argue the program would impose hundreds of millions of dollars in costs that would lead 340B hospitals to cut services.
  1. The brief challenges drugmakers’ claims of harm without the program, noting AbbVie projects $35.8 million in duplicate discount losses in 2027 but bought back $1.1 billion of its stock in the first nine months of 2026.
Advertisement

Next Up in Pharmacy

Advertisement